July 20, 2024
Discover innovative therapeutic strategies targeting quiescent cancer cells to combat tumor resistance and prevent relapse. Learn how to overcome treatment challenges.
April 12, 2024
Mercaptopurine, often referred to by its chemical name 6-mercaptopurine or simply 6-MP, stands as a pivotal medication in the oncology sphere, particularly within the context of treating childhood Acute Lymphoblastic Leukemia (ALL).
February 26, 2024
Mannitol is used after cisplatin treatment to prevent or reduce the risk of cisplatin-induced nephrotoxicity, which is a major concern associated with cisplatin chemotherapy. Cisplatin is a widely used chemotherapeutic drug for various types of cancer, but its use is often limited by its potential to cause kidney damage.
February 24, 2024
Heparin, available as both unfractionated and low-molecular-weight forms, has been extensively studied for its potential benefits in cancer patients. Low molecular weight heparin's role in both preventing and treating venous thromboembolism in patients, a common complication in cancer patients, has been the subject of systematic review and numerous randomized clinical trials. Furthermore, heparin has shown promising effects in managing VTE in patients undergoing cancer therapy, including those with advanced pancreatic cancer.
February 7, 2024
The development of Enhertu represents a significant advancement in targeted cancer therapy, offering new hope for patients with limited treatment options. Enhertu, also known as trastuzumab deruxtecan, is an innovative antibody-drug conjugate (ADC) designed to target HER2-positive cancers, which are associated with aggressive growth and poor prognosis in various cancer types, including breast and gastric cancers
January 22, 2024
"for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."
January 19, 2024
Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
August 12, 2021
Abraxane - Paclitaxel is a medication that belongs to a family of medications known as chemotherapy medicines. Oncogene therapy works by reducing or halting the development of cancer cells.
June 28, 2021
One important thing to note about oncology protocols pairing is that there is no single oncology drug or combination of drugs that is suitable for every patient.
